Achillion Pharmaceuticals (NASDAQ:ACHN): 6 Brokerage firm Analysts have agreed with the mean estimate for the short term price target of $9.5 in Achillion Pharmaceuticals (NASDAQ:ACHN). However, the stock price could fluctuate by $ 3.39 from the estimate as it is suggested by the standard deviation reading. The higher estimate has been put at $16 price target with the lower price estimate is calculated at $7
Many analysts have stated their opinion on the company shares. Major Brokerage house, Leerink Swann maintains its ratings on Achillion Pharmaceuticals (NASDAQ:ACHN). In the latest research report, Leerink Swann raises the target price from $7 per share to $9 per share. According to the latest information available, the shares are now rated Market Perform by the analysts at the agency. The rating by the firm was issued on May 4, 2016. For the current week, the company shares have a recommendation consensus of Buy.
On the companys insider trading activities, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the officer (Chief Financial Officer) of Achillion Pharmaceuticals Inc, Fenton Mary Kay had sold 43,500 shares worth of $438,480 in a transaction dated December 28, 2015. In this transaction, 43,500 shares were sold at $10.08 per share.
Achillion Pharmaceuticals (NASDAQ:ACHN) stock ended Monday session in the red zone in a volatile trading. The stock closed down 0.44 points or 4.61% at $9.11 with 1,820,627 shares getting traded. Post opening the session at $9.51, the shares hit an intraday low of $9.08 and an intraday high of $9.63 and the price was in this range throughout the day. The company has a market cap of $1,245 million and the number of outstanding shares have been calculated to be 136,640,020 shares. The 52-week high of Achillion Pharmaceuticals (NASDAQ:ACHN) is $10.95 and the 52-week low is $5.57.
Achillion Pharmaceuticals, Inc. is a biopharmaceutical company. The Companys primary business is to discover, develop and commercialize small molecule therapeutics for the treatment of infectious diseases and immune system disorders. The Company is focused on developing short-duration combination therapies for the treatment of chronic hepatitis C virus, or HCV, infection that are once-daily and ribavirin-free. The Company is advancing several combination regimens, including ACH-3102, a NS5A inhibitor, which is under Phase II clinical development, ACH-3422, a NS5B nucleotide polymerase inhibitor, which is under Phase I clinical development, and Sovaprevir, a NS3 protease inhibitor, which is under Phase II clinical development.